These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17855736)

  • 21. Benefits and risks of aprotinin use during cardiac surgery.
    Kristeller JL; Roslund BP; Stahl RF
    Pharmacotherapy; 2008 Jan; 28(1):112-24. PubMed ID: 18154481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aprotinin dosing: how much is enough?
    Niimi KS
    J Extra Corpor Technol; 2004 Dec; 36(4):384-90. PubMed ID: 15679284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
    Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
    Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprotinin and renal dysfunction after pediatric cardiac surgery.
    Székely A; Sápi E; Breuer T; Kertai MD; Bodor G; Vargha P; Szatmári A
    Paediatr Anaesth; 2008 Feb; 18(2):151-9. PubMed ID: 18184247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aprotinin use in cardiac surgery patients at low risk for requiring blood transfusion.
    Kristeller JL; Stahl RF; Roslund BP; Roke-Thomas M
    Pharmacotherapy; 2007 Jul; 27(7):988-94. PubMed ID: 17594204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
    Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
    Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased incidence of acute kidney injury with aprotinin use during cardiac surgery detected with urinary NGAL.
    Wagener G; Gubitosa G; Wang S; Borregaard N; Kim M; Lee HT
    Am J Nephrol; 2008; 28(4):576-82. PubMed ID: 18264006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study.
    Ngaage DL; Cale AR; Cowen ME; Griffin S; Guvendik L
    Ann Thorac Surg; 2008 Oct; 86(4):1195-202. PubMed ID: 18805159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin.
    Dietrich W; Busley R; Boulesteix AL
    Anesthesiology; 2008 Feb; 108(2):189-98. PubMed ID: 18212563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting.
    Bittner HB; Lemke J; Lange M; Rastan A; Mohr FW
    Ann Thorac Surg; 2008 May; 85(5):1662-8. PubMed ID: 18442562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aprotinin, blood loss, and renal dysfunction in deep hypothermic circulatory arrest.
    Mora Mangano CT; Neville MJ; Hsu PH; Mignea I; King J; Miller DC
    Circulation; 2001 Sep; 104(12 Suppl 1):I276-81. PubMed ID: 11568069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of aprotinin in cardiac surgery.
    Levy JH
    Orthopedics; 2004 Jun; 27(6 Suppl):s659-62. PubMed ID: 15239553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a high-dose aprotinin regimen for reducing transfusion requirements and inflammatory responses in adult cardiac surgery.
    Jeong DS; Kim KH; Kim CY; Kim JS
    J Int Med Res; 2008; 36(5):1039-48. PubMed ID: 18831899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.
    Davis R; Whittington R
    Drugs; 1995 Jun; 49(6):954-83. PubMed ID: 7543841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass.
    Ray MJ; Marsh NA; Just SJ; Perrin EJ; O'Brien MF; Hawson GA
    Ann Thorac Surg; 1997 Jan; 63(1):57-63. PubMed ID: 8993241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
    Mangano DT; Miao Y; Vuylsteke A; Tudor IC; Juneja R; Filipescu D; Hoeft A; Fontes ML; Hillel Z; Ott E; Titov T; Dietzel C; Levin J; ;
    JAMA; 2007 Feb; 297(5):471-9. PubMed ID: 17284697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replacement of aprotinin by ε-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome.
    Martin K; Gertler R; MacGuill M; Mayr NP; Hapfelmeier A; Hörer J; Vogt M; Tassani P; Wiesner G
    Br J Anaesth; 2013 Apr; 110(4):615-21. PubMed ID: 23213034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aprotinin in cardiac surgery.
    Sodha NR; Boodhwani M; Bianchi C; Ramlawi B; Sellke FW
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):151-60. PubMed ID: 16509811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
    Karkouti K; Beattie WS; Dattilo KM; McCluskey SA; Ghannam M; Hamdy A; Wijeysundera DN; Fedorko L; Yau TM
    Transfusion; 2006 Mar; 46(3):327-38. PubMed ID: 16533273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
    Vonk AB; Meesters MI; Schats J; Romijn JW; Jansen EK; Boer C
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):135-9. PubMed ID: 21075830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.